Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Prevention of mother-to-child transmission programs serve women continuing and initiating antiretroviral therapy (ART) in pregnancy, and follow-up schedules align to delivery rather than ART initiation, making conventional HIV retention measures (assessed from ART initiation) challenging to apply. We evaluated 3 measures of peripartum nonretention in Kenyan women living with HIV from pregnancy to 2 years postpartum.

Methods: This longitudinal analysis used programmatic data from the Mobile WAChX trial (NCT02400671). Outcomes included loss to follow-up (LTFU) (no visit for ≥6 months), incomplete visit coverage (<80% of 3-month intervals with a visit), and late visits (>2 weeks after scheduled date). Predictors of nonretention were determined using Cox proportional hazards, log-binomial, and generalized estimating equation models.

Results: Among 813 women enrolled at a median of 24 weeks gestation, incidence of LTFU was 13.6/100 person-years; cumulative incidence of LTFU by 6, 12, and 24 months postpartum was 16.7%, 20.9%, and 22.5%, respectively. Overall, 35.5% of women had incomplete visit coverage. Among 794 women with 12,437 scheduled visits, a median of 11.1% of visits per woman were late (interquartile range 4.3%-23.5%). Younger age, unsuppressed viral load, unemployment, ART initiation in pregnancy, and nondisclosure were associated with nonretention by all measures. Partner involvement was associated with better visit coverage and timely attendance. Women who became LTFU had higher frequency of previous late visits (16.7% vs. 7.7%, P < 0.0001).

Conclusions: Late visit attendance may be a sentinel indicator of LTFU. Identified cofactors of prevention of mother-to-child transmission programmatic retention may differ depending on retention measure assessed, highlighting the need for standardized measures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839514PMC
http://dx.doi.org/10.1097/QAI.0000000000003117DOI Listing

Publication Analysis

Top Keywords

prevention mother-to-child
12
mother-to-child transmission
12
art initiation
12
visit coverage
12
programmatic retention
8
nonretention measures
8
incomplete visit
8
incidence ltfu
8
women
6
measures
5

Similar Publications

Hepatitis B virus (HBV) is a potentially chronic infection that can be transmitted from mother to child with the risk of developing cirrhosis, liver failure and hepatocellular carcinoma. There is a safe and effective vaccine to prevent vertical transmission that is recommended to be given as soon as possible after birth and within 24 hours.When a woman with HBV refuses the birth dose of HBV vaccine for her baby, infectious diseases and safeguarding teams are asked to provide urgent opinions on whether this crosses the threshold for triggering child protection mechanisms.

View Article and Find Full Text PDF

To evaluate progress toward MTCT elimination of HBV, we analyzed 8-y trends in hepatitis B vaccine (HepB) and hepatitis B immune globulin (HBIG) administration coverage rates in Shandong province, focusing on high-risk populations. Data were collected from a provincial system, Shandong Vaccination Information System. Information of maternal HBsAg+ neonates born in 2017-2024 were extracted.

View Article and Find Full Text PDF

[Treatment of adult T-cell leukemia/lymphoma: past, present, and future].

Rinsho Ketsueki

September 2025

Department of Hematology and Rheumatology, Kagoshima University.

Adult T-cell leukemia/lymphoma (ATL) is a T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1). Treatment strategies have been established by classification of ATL as aggressive (acute, lymphoma, and chronic ATL with any unfavorable prognostic factors) or indolent (smoldering and chronic ATL without any unfavorable prognostic factors). The standard of care (SOC) for aggressive ATL has been dose-intensified multi-agent chemotherapy.

View Article and Find Full Text PDF

Background: To investigate the impact of tenofovir disoproxil fumarate (TDF) withdrawal timing on elevated postpartum alanine aminotransferase (ALT) levels and breastfeeding in pregnant women who received TDF therapy to prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection.

Methods: All enrolled women began treatment with TDF during weeks 24-32 of pregnancy and were divided into three groups that stopped TDF at delivery (Group A), at 4 weeks postpartum (Group B), or at 12 weeks postpartum (Group C). The biochemical and virological markers of hepatitis B were regularly measured and compared.

View Article and Find Full Text PDF

HIV mother-to-child transmission (MTCT) continues to pose a significant public health challenge, especially in regions with limited resources, although the worldwide distribution of antiretroviral therapy (ART) has drastically lowered the risk of vertical transmission to even below 1% in some regions. There are still uncertainties regarding the safety of some ART regimens during pregnancy and their longer-term effects on infants who are perinatally exposed to HIV but remain uninfected. This review explores current evidence regarding the interplay between maternal HIV infection, ART during pregnancy, and both maternal and pediatric outcomes.

View Article and Find Full Text PDF